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Background:  Emerging evidence suggests a role for resistin in inflammation and vascular dysfunction, which may contribute to the pathogenesis 
of hypertension. However the association between resistin levels and response to antihypertensive medication is still unknown. In this study, we 
investigated the effect of serum resistin levels on blood pressure control and antihypertensive treatment in new-onset stage I essential hypertension
Methods:  Our study population is consisted 85 untreated nondiabetic patients with newly diagnosed stage I essential hypertension (50 females, 
mean age: 52 ± 8, basal blood pressure (BP):153/94 mm Hg ). All of the patients were treated with single agent antihypertensive agent (42 
olmesartan, 43 nebivolol). Systolic and diastolic BP measurements, plasma resistin plasma levels (ELISA) were determined in the whole study 
population before and 12 weeks after the beginning of treatment.
Results:  The goal of target blood pressure <140/90 was achieved in 68% of the patients. Patients with higher basal serum resistin levels did 
not differ by age, gender, body mass index (BMI) smoking status and basal blood pressure levels compared to those with low resistin values. Basal 
resistin levels were higher in patints unresponsive to antihypertensive medication compared to responders (2.6 ± 1.2 ng/ml vs. 2.0±1.3 ng/ml, 
p=0,021). The reduction in serum resisitin levels was not significant after 12 weeks of treatment (2.0 ± 1.2 non vs 1.7 ± 1.1, p=0.19) (Figure). 
Multivariate regression analysis revelaed that basal resistin level was an independent predictor of poor BP control after addustment of other factors 
including age, gender, smoking and BMI (b=0.576, P<0.05).
Conclusions:  Our study findings suggest that in new onset stage I hypertension, higher plasma resistin levels are independently associated with 
an increased risk of poor blood pressure response to single agent antihypertensive therapy. Large scale studies are needed to determine the clinical 
significance of higher basal resistin levels to begin a more agressive antihypertensive treatment in this population.
